Peptide-Based Therapeutic Cancer Vaccines

Melief, Cornelis J.M.

doi:10.1007/978-3-319-62431-0_14

Cited by 5 publications

(2 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Synthetic long peptides (LPs) consisting of 20-40 amino acid sequences, which often include an 8-11 amino acid minimal ("Min") CD8 T cell epitope, combined with various adjuvants have been widely studied as cancer vaccines 30,31 . However, it is not well understood how differences in the amino acid composition, which determines the physical form (i.e.…”

Section: Peptide Physical Form Is a Key Determinant Of Cd8 T Cell Immmentioning

confidence: 99%

Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens

et al. 2020

View full text Add to dashboard Cite

Personalized cancer vaccines (PCVs) targeting patient-specific neoantigens are a promising cancer treatment modality; however, neoantigen physicochemical variability can present challenges to manufacturing PCVs in an optimal format for inducing anticancer T cells. Here, we developed a vaccine platform ("SNP-7/8a") based on charge-modified peptide-TLR-7/8a conjugates that are chemically programmed to self-assemble into nanoparticles of uniform size (~20 nm) irrespective of the peptide antigen composition. This approach provided precise loading of diverse peptide neoantigens linked to TLR-7/8a (adjuvant) in nanoparticles that increased uptake by and activation of antigen-presenting cells that promote T cell immunity. Vaccination of mice with SNP-7/8a using predicted neoantigens (n=179) from three tumor models induced CD8 T cells against ~50% of neoantigens with high predicted MHC-I binding affinity and led to enhanced tumor clearance. SNP-7/8a delivering in silico-designed mock neoantigens also induced CD8 T cells in non-human primates. Altogether, SNP-7/8a is a generalizable approach for co-delivering peptide antigens and adjuvants in nanoparticles for inducing anticancer T cell immunity.

show abstract

Section: Peptide Physical Form Is a Key Determinant Of Cd8 T Cell Immmentioning

confidence: 99%

Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In the actual treatment, it can be found that some tumor patients can only express partial antigen proteins, which unable to fully active the immune cell. Some experts [7][8] study the whole tumor lysate or embryonic stem cells as vaccines. Taking tumor bearing rats as the research object, H22 or S180 cancer cell lysate was given to them.…”

Section: Whole Tumor Lysate Vaccinementioning

confidence: 99%

Research Status of Tumor Therapy Based on Immunotherapy

2022

FMSR

View full text Add to dashboard Cite

Cancer is the "top killer" of human health. Traditional cancer treatment methods include surgery, radiotherapy and chemotherapy, but all of them are carried out by directly killing cancer cells, which is difficult to completely remove cancer cells and cause serious damage to normal cells and tissues. Different from traditional treatments, immunotherapy destroys tumors by regulating the body's immune defense mechanism without damaging normal cells and tissues. This paper first introduces the characteristics of immunotherapy, and expounds the research status of tumor therapy based on immunotherapy from two aspects of active immunotherapy and passive immunotherapy, aiming to provide theoretical reference for tumor drug research and promote tumor immunotherapy to achieve greater breakthroughs.

show abstract

Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy

Song

Nie

et al. 2023

Acta Biomaterialia

View full text Add to dashboard Cite

Peptide-Based Therapeutic Cancer Vaccines

Cited by 5 publications

References 79 publications

Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens

Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens

Research Status of Tumor Therapy Based on Immunotherapy

Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy

Contact Info

Product

Resources

About